Beta-Amyloid Imaging With PET & [18F]NAV4694 in Predicting Progression to Alzheimer’s Disease (AD) in People with Mild Memory Loss

What we are studying

This is a research study for the investigational drug [18F]NAV4694 used as a brain imaging drug in positron emission tomography (PET). PET is a way to look at a picture of the inside of the body. The purpose of this study is to evaluate the safety of [18F]NAV4694 and to see how well it works in the detection of protein deposits in the brain. The study drug sticks to a special type of protein in the brain and can be seen in pictures taken using a PET/CT scanner. This protein has been linked to people who have dementia or Alzheimer’s disease or may develop Alzheimer’s disease.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 55+

Eligibility Criteria

  • Ability to sign informed consent
  • At least 6 years of education
  • Must have a study partner available to attend all study visits
  • Memory complaints confirmed by study partner
  • Has not received an inverstgational product within the past 30 days proior to screening
  • Does not have a history of alcohol abuse or dependency in 3 years prior to study entry
  • Has not been diagnosed with parkinson's disease.

What is involved

  • Give blood and urine samples (up to 7 times)
  • Tests of memory
  • Thinking skills
  • Daily functioning and behavior (up to 8 times)
  • MRI scans of your brain (3 times)
  • PET/CT scans of your brain (up to 3 times)

Contact Information

Study Coordinator
Rose Fries
Email
rfries@wakehealth.edu
Phone
336-713-8462
Principal Investigator
Kaycee Sink, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.